Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Spectrum Pharmaceuticals

DB:NTR
Snowflake Description

Flawless balance sheet and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NTR
DB
$240M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The last earnings update was 34 days ago. More info.


Add to Portfolio Compare Print
  • Spectrum Pharmaceuticals has significant price volatility in the past 3 months.
NTR Share Price and Events
7 Day Returns
-9%
DB:NTR
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-79.2%
DB:NTR
-13.2%
DE Biotechs
-20.9%
DE Market
NTR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Spectrum Pharmaceuticals (NTR) -9% -21.7% -27.3% -79.2% -64.7% -63.3%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • NTR underperformed the Biotechs industry which returned -13.2% over the past year.
  • NTR underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
NTR
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Spectrum Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Spectrum Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Spectrum Pharmaceuticals.

DB:NTR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.8%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:NTR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.19
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.188 (1 + (1- 21%) (1.69%))
1.137
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.14
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.137 * 5.44%)
5.79%

Discounted Cash Flow Calculation for DB:NTR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Spectrum Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:NTR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.79%)
2020 -180.40 Analyst x1 -170.52
2021 -96.50 Analyst x2 -86.22
2022 14.10 Analyst x2 11.91
2023 119.25 Analyst x2 95.20
2024 190.50 Analyst x2 143.75
2025 246.60 Est @ 29.45% 175.89
2026 297.14 Est @ 20.5% 200.34
2027 339.42 Est @ 14.23% 216.32
2028 372.83 Est @ 9.84% 224.60
2029 398.09 Est @ 6.77% 226.68
Present value of next 10 years cash flows $1,037.00
DB:NTR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $398.09 × (1 + -0.39%) ÷ (5.79% – -0.39%)
$6,413.63
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $6,413.63 ÷ (1 + 5.79%)10
$3,652.14
DB:NTR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,037.00 + $3,652.14
$4,689.14
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,689.14 / 112.03
$41.86
DB:NTR Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:NTR represents 0.94392x of NasdaqGS:SPPI
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.94392x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 41.86 x 0.94392
€39.51
Value per share (EUR) From above. €39.51
Current discount Discount to share price of €2.02
= -1 x (€2.02 - €39.51) / €39.51
94.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Spectrum Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €2.02 vs Future cash flow value of €39.51
Current Discount Checks
For Spectrum Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Spectrum Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Spectrum Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Spectrum Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Spectrum Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NTR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-1.22
NasdaqGS:SPPI Share Price ** NasdaqGS (2020-04-03) in USD $2.14
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Spectrum Pharmaceuticals.

DB:NTR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:SPPI Share Price ÷ EPS (both in USD)

= 2.14 ÷ -1.22

-1.75x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Spectrum Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Spectrum Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Spectrum Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:NTR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.75x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
32.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Spectrum Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Spectrum Pharmaceuticals's assets?
Raw Data
DB:NTR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $1.71
NasdaqGS:SPPI Share Price * NasdaqGS (2020-04-03) in USD $2.14
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:NTR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:SPPI Share Price ÷ Book Value per Share (both in USD)

= 2.14 ÷ 1.71

1.25x

* Primary Listing of Spectrum Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Spectrum Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Spectrum Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Spectrum Pharmaceuticals has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Spectrum Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
32.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Spectrum Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Spectrum Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Spectrum Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Spectrum Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NTR Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NTR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 32.5%
DB:NTR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 39.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NTR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NTR Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 184 407 -18 3
2023-12-31 159 278 -32 3
2022-12-31 142 99 -70 5
2021-12-31 73 -82 -139 5
2020-12-31 4 -120 -175 5
2020-04-05
DB:NTR Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -135 -135
2019-09-30 109 -116 -142
2019-06-30 109 -100 -184
2019-03-31 109 -76 -141
2018-12-31 -62 -127
2018-09-30 29 -63 -102
2018-06-30 65 -59 -51
2018-03-31 99 -45 -87
2017-12-31 -39 -101
2017-09-30 135 -29 -81
2017-06-30 132 -36 -81
2017-03-31 132 -54 -84

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Spectrum Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Spectrum Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NTR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Spectrum Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NTR Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 0.45 1.59 -0.29 3.00
2023-12-31 -0.22 -0.11 -0.32 2.00
2022-12-31 -0.54 -0.23 -1.04 5.00
2021-12-31 -1.04 -0.84 -1.20 5.00
2020-12-31 -1.55 -1.38 -1.70 5.00
2020-04-05
DB:NTR Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -1.22
2019-09-30 -1.30
2019-06-30 -1.72
2019-03-31 -1.33
2018-12-31 -1.23
2018-09-30 -1.00
2018-06-30 -0.53
2018-03-31 -0.96
2017-12-31 -1.18
2017-09-30 -1.02
2017-06-30 -1.03
2017-03-31 -1.10

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Spectrum Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Spectrum Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Spectrum Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Spectrum Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Spectrum Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Spectrum Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Spectrum Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Spectrum Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Spectrum Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Spectrum Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NTR Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -135.39 59.87 79.03
2019-09-30 109.33 -141.72 89.39 105.42
2019-06-30 109.33 -184.34 89.38 103.56
2019-03-31 109.33 -140.66 88.34 102.98
2018-12-31 -126.71 62.69 75.16
2018-09-30 28.57 -102.01 68.23 67.41
2018-06-30 64.97 -51.13 73.65 65.91
2018-03-31 99.27 -86.87 74.68 64.48
2017-12-31 -100.75 64.76 51.53
2017-09-30 135.03 -81.39 72.02 62.55
2017-06-30 132.03 -80.55 72.96 59.32
2017-03-31 131.68 -84.00 83.16 58.44
2016-12-31 146.44 -69.77 86.02 59.12
2016-09-30 161.54 -55.22 92.36 55.77
2016-06-30 156.77 -56.49 92.31 55.10
2016-03-31 167.80 -34.54 87.24 50.38
2015-12-31 162.56 -52.64 88.06 51.07
2015-09-30 164.09 -49.61 89.78 49.74
2015-06-30 183.45 -42.42 94.50 54.24
2015-03-31 185.32 -43.64 97.34 73.81
2014-12-31 186.83 -45.72 97.41 69.66
2014-09-30 176.49 -82.12 97.94 66.01
2014-06-30 170.93 -78.18 98.52 65.16
2014-03-31 157.31 -84.34 95.00 46.49
2013-12-31 155.85 -62.13 93.62 46.67
2013-09-30 184.44 -15.27 86.09 49.63
2013-06-30 211.05 13.86 84.32 46.08

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Spectrum Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Spectrum Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Spectrum Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Spectrum Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Spectrum Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Spectrum Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Spectrum Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Spectrum Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Spectrum Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Spectrum Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Spectrum Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Spectrum Pharmaceuticals Company Filings, last reported 3 months ago.

DB:NTR Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 190.39 0.00 223.87
2019-09-30 234.72 0.00 247.76
2019-06-30 254.78 0.00 288.93
2019-03-31 272.55 0.00 312.64
2018-12-31 271.41 0.00 203.99
2018-09-30 286.78 35.36 220.56
2018-06-30 344.12 39.43 269.66
2018-03-31 324.29 38.82 231.92
2017-12-31 351.34 38.22 227.57
2017-09-30 304.74 101.77 247.72
2017-06-30 198.77 100.16 138.56
2017-03-31 217.37 98.59 137.44
2016-12-31 236.03 97.04 158.47
2016-09-30 250.80 104.14 171.85
2016-06-30 235.90 102.52 156.01
2016-03-31 208.32 100.93 132.55
2015-12-31 212.86 99.38 139.99
2015-09-30 214.74 100.19 136.77
2015-06-30 234.14 98.87 145.58
2015-03-31 230.37 97.57 126.67
2014-12-31 254.55 96.30 133.25
2014-09-30 256.59 95.04 147.54
2014-06-30 265.65 93.81 135.71
2014-03-31 265.85 92.63 134.80
2013-12-31 281.61 91.48 159.78
2013-09-30 302.36 25.00 75.29
2013-06-30 279.24 50.00 124.42
  • Spectrum Pharmaceuticals has no debt.
  • Spectrum Pharmaceuticals has no debt compared to 5 years ago when it was 37.9%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Spectrum Pharmaceuticals has sufficient cash runway for 1.6 years based on current free cash flow.
  • Spectrum Pharmaceuticals has sufficient cash runway for 1.5 years if free cash flow continues to grow at historical rates of 37.2% each year.
X
Financial health checks
We assess Spectrum Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Spectrum Pharmaceuticals has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Spectrum Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Spectrum Pharmaceuticals dividends.
If you bought €2,000 of Spectrum Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Spectrum Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Spectrum Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NTR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NTR Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-05

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Spectrum Pharmaceuticals has not reported any payouts.
  • Unable to verify if Spectrum Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Spectrum Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Spectrum Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Spectrum Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Spectrum Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Spectrum Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Spectrum Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joe Turgeon
COMPENSATION $4,722,227
AGE 61
TENURE AS CEO 2.3 years
CEO Bio

Mr. Joseph W. Turgeon, also known as Joe, has been the President of Spectrum Pharmaceuticals, Inc. since April 2014 and its Chief Executive Officer since December 17, 2017. Mr. Turgeon served as the Chief Operating Officer of Spectrum Pharmaceuticals, Inc. from April 2014 to December 17, 2017. He served as the Chief Commercial Officer and Senior Vice President at Spectrum Pharmaceuticals, Inc. from October 2012 to April 2014. Mr. Turgeon served as Senior Vice President of Sales and Commercial Operations at Spectrum Pharmaceuticals, Inc. from October 29, 2012 to January 2013. He is a Director at Spectrum Pharmaceuticals, Inc. from December 2017. Mr. Turgeon came to Spectrum from Amgen where he spent more than 22 years including as Vice President of Sales, Oncology. He has over 30 years of relevant biotech and pharmaceutical experience. He is a Visionary leader and has built and led sales organizations at Amgen across multiple areas, including oncology, inflammation and bone health. Mr. Turgeon holds a Bachelor of Science in Microbiology and Economics from Jacksonville University.

CEO Compensation
  • Joe's compensation has increased whilst company is loss making.
  • Joe's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Spectrum Pharmaceuticals management team in years:

2.3
Average Tenure
47
Average Age
  • The tenure for the Spectrum Pharmaceuticals management team is about average.
Management Team

Joe Turgeon

TITLE
President
COMPENSATION
$5M
AGE
61
TENURE
2.3 yrs

Kurt Gustafson

TITLE
Executive VP
COMPENSATION
$3M
AGE
51
TENURE
6.8 yrs

Tom Riga

TITLE
Executive VP
COMPENSATION
$5M
AGE
43
TENURE
2.3 yrs

Keith McGahan

TITLE
Senior VP
COMPENSATION
$5M
AGE
43
TENURE
1.8 yrs

Shiv Kapoor

TITLE
Vice President of Strategic Planning & Investor Relations

Bimal Shah

TITLE
Vice President of Corporate & Business Development

Al Dejesus

TITLE
Vice President of Marketing

Lisa Croissant

TITLE
Vice President of Sales

Zane Yang

TITLE
Senior Vice President of Clinical Development
TENURE
3.6 yrs

Michael Grabow

TITLE
Senior Vice President of Corporate Strategy & Operations
TENURE
2.1 yrs
Board of Directors Tenure

Average tenure and age of the Spectrum Pharmaceuticals board of directors in years:

1.8
Average Tenure
63
Average Age
  • The average tenure for the Spectrum Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Bill Ashton

TITLE
Independent Chairman of the Board
COMPENSATION
$544K
AGE
68
TENURE
0.8 yrs

Joe Turgeon

TITLE
President
COMPENSATION
$5M
AGE
61
TENURE
2.3 yrs

Ray Cohen

TITLE
Independent Director
COMPENSATION
$483K
AGE
60
TENURE
6.8 yrs

Bernice Welles

TITLE
Independent Director
COMPENSATION
$421K
AGE
66
TENURE
1.8 yrs

Elizabeth Czerepak

TITLE
Independent Director
AGE
63
TENURE
0.8 yrs

Dinesh Vyas

TITLE
Independent Director
COMPENSATION
$458K
AGE
75
TENURE
6.8 yrs

Jeff Vacirca

TITLE
Independent Director
COMPENSATION
$214K
AGE
50
TENURE
1.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
29. May 19 Sell Stuart Krassner Individual 28. May 19 28. May 19 -37,385 €7.16 €-267,617
X
Management checks
We assess Spectrum Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Spectrum Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company offers KHAPZORY, a novel folate analog and the pharmacologically active levo-isomer of d, and 1-leucovorin; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection to treat non-Hodgkin’s lymphoma; MARQIBO for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ, a histone deacytelase, or HDAC, inhibitor for the treatment of patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB, a pan-HER inhibitor for non-small cell lung cancer tumors; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly to hospitals and cancer centers in the United States; and through distributors in Europe. It has a strategic partnership with Servier Canada, Inc.; licensing and development agreement with Cell Therapeutics, Inc.; license agreements with Merck & Cie AG, Medac Pharma, Inc., Sloan-Kettering Institute for Cancer Research, SRI International, Southern Research Institute, Medac Pharma, Inc., Cydex Pharmaceuticals, Inc., and Mundipharma International Corporation Limited; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreements with Hanmi Pharmaceutical Co. Ltd and The University of Texas MD Anderson Cancer Center. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.

Details
Name: Spectrum Pharmaceuticals, Inc.
NTR
Exchange: DB
Founded: 1987
$222,219,103
112,030,103
Website: http://www.sppirx.com
Address: Spectrum Pharmaceuticals, Inc.
11500 South Eastern Avenue,
Suite 240,
Henderson,
Nevada, 89052,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS SPPI Common Shares Nasdaq Global Select US USD 26. Sep 1996
DB NTR Common Shares Deutsche Boerse AG DE EUR 26. Sep 1996
BRSE NTR Common Shares Berne Stock Exchange CH CHF 26. Sep 1996
Number of employees
Current staff
Staff numbers
146
Spectrum Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 23:57
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/17
Last earnings filing: 2020/03/02
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.